Bisphosphonates in oncology;Les bisphosphonates en cancerologie

Presse Medicale

Volumn 29, Issue 13, 2000, Pages 723-729

  Paule, B ^a   Clerc, D ^a   Brion, N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER; CLINICAL TRIAL; HUMAN; HYPERCALCEMIA; MYELOMA; PATHOLOGIC FRACTURE; REVIEW; SPINAL CORD COMPRESSION; ARTICLE; BONE TUMOR; FRACTURE; METASTASIS; NEOPLASM; OSTEOLYSIS; PAIN;

BONE NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; NEOPLASMS; OSTEOLYSIS; PAIN; SPINAL CORD COMPRESSION;

EID: 0034620854     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Colman RC, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987 ; 55:61-6.
2. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions. N Engl J Med 1996 ; 335:1785-91.
3. Lipton A, Theriault R, Left R et al. Long term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate (Aredia) infusion. Proc Am Soc Clin Oncol 1997 ; 16:152 a.
4. Berenson JR. Bisphosphonates in multiple myeloma. Cancer 1997 ; 80 Suppl 1661-7.
5. Body JJ, Bartl R, Burckhardt P et al. For the International Bone and Cancer Study Group. Current use of bisphosphonates in oncology. J Clin Oncol 1998 ; 16:3890-9.
6. Broadus AE, Mangin M, Ikeda K et al. Humoral hypercalcemia of cancer identification of a novel parathroid hormone-like peptide. New Engl J Med 1988 ; 319:556-63.
7. Clerc D, Paule B. Physiopathogénie des métastases osseuses. Rev Rhum (Ed Fr) 1999 ; 66:179-83, (Engl Ed) 1999 ; 66:158-65.
8. Clerc D, Paule B. Physiopathogénie des métastases osseuses. Rev Rhum (Ed Fr) 1999 ; 66:179-83, (Engl Ed) 1999 ; 66:158-65.
9. Mundy GR, Yoneda T. Editorial. N Engl J Med 1998 ; 399:398-400.
10. Guise TA, Yin JJ, Taylor SD et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996 ; 98:1544-9.
11. Yin JJ, Spinks TJ, Cui Y, Dallas M. Cloral variation in parathyroid hormone-related protein (PTH-rP) reaction by a human breast cancer cell line alters severity of osteolytic metastases. J Bone Miner Res 1997 ; 12 Suppl S107 Abstract.
12. Hughes DE, Wright KR, Uly HL. Bisphophonates promote apoptose in murine osteodasts in vitro and in vivo. J Bone Miner Res 1995 ; 10:1478-87.
13. Shebata M, Scharzmeier M et al. Bisphosphonates (alendronate)-induced apoptosis in human lung adeno-carcinoma cells is suppresed by geranylgeranyl pyrophosphate. J Bone Miner Res 1998 ; 13(Suppl):S280, Abst T 334.
14. Simpson E, Harrod J, Eilon G et al. Identification of a messanger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 1985 ; 117-20.
15. Koutsillieris M, Rabbani SA, Bennet HP et al. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987 ; 80:941-6.
16. Rabbani SA, Desjardins J, Bell AW et al. An amino-terminal fragment of urokinase osolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biophys Res Commn 1990 ; 173:1058-64.
17. Clarke NW, MacClure J, George NJR. Morphologic evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991 ; 68:74-80.
18. Adami S. Bisphosphonates in prostate carcinoma Cancer 1997 ; 80 suppl 1674-9.
19. Averbusch SD. New bisphosphonates in the treatment of bone metastases. Cancer 1993 ; 72:3443-5.
20. Sasaki A, Boyce BF, Story B et al. Bisphosphonates risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995 ; 55:3551-7.
21. Boissier S, Magnetto S, Trappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralyzed and mineralized bone extracellular matrices. Cancer Res 1997 ; 57:9890-4.
22. Van der Pluijm G, Vloedgraven H, van Beck E et al. Bisphophonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996 ; 98:698-705.
23. Vargas SJ, Gillispie MT, Powell GJ et al. Localization of parathyroid hormone - related protein m-RNA expression and metastatic lesions by in situ hybridation. J Bone Miner Res 1992 ; 7:971-80.
24. Bouizar TA, Syrapos F, Deytieux S, Vernejoul MC de, Julienne A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993 ; 53:5076-8.
25. Brended NJ, Tatcliffe WA, Walker RA et al. Parathyroid hormone related proteine and hypercalcemia in breast cancer. Br Med J 1991 ; 303:1506-9.
26. Klein B, Zhang XG, Jourdan M et al. Paracrine rather autocrine regulation of myeloma - cell growth and differenciation of interleukin 6. Blood 1989 ; 73:517-26.
27. Kawano MM, Mahmod MS, Huang K et al. High proportions of VLA-5 immature cells correlates well with poor response to treatment in multiple myeloma. Br J Haematol 1995 ; 91:860-4.
28. Passeri G, Girasole G, Uliette V et al. Bisphosphonates inhibit IL-6 production by human osteoblastic cells MG 63. J Bone Miner Res 1994 ; 9 suppl 1, S230.
29. Nishikawa M, Akatsu T, Katayama Y et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996 ; 18:9-14.
30. Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996 ; 85, 105a.
31. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997 ; 98:665-72.
32. Aparicio A, Gardner A, Tu Y et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998 ; 12:220-9.
33. Radl J, Croese JW, Zurcker C et al. Influence of treatment with ADP-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma Cancer 1985 ; 55:1030-6.
34. Croese JW, Zurcker C, Van den Enden-Vieveen MHM et al. Effect of long term treatment with the bisphosphonate APD on 5T2 mouse multiple myeloma in Radl and Van Camp B (eds). Monoclonal gammapathies III: clinical significance and basic mechanisms. Topics in aging research in Europ, Vol 14 Leiden The Netherlands. EURAGE 1991 ; p199.
35. Yaccoby S, Barlogie B, Epsten J. Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system. Am Soc Hematol 1998 ; Abst 435.
36. Kurzmann V, Feurle J, Bauer E, Henderich M, Wilhelm M. Pamidronate induces gd T cell expansion in vivo and mediates artiplasma cell activity in multiple myeloma. Am Soc Hematol 1998 ; Abst 4203.
37. Dallasd SL, Ganett IR, Oyajobi BO et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine modele of myeloma bone disease. Blood 1999 ; 93:1697-706.
38. Purohit OP, Radsone CR, Anthony C et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995 ; 72:1289-93.
39. Gurney H, Grill V, Martin TJ. Parathyroid hormone related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet 1993 ; 341:1611-13.
40. Dodwell DJ, Abbas SK, Morton AR et al. Parathyroid hormone-related protein (50-69) and response to pamidronate therapy for tumor-induced hypercalcemia. Eur J Cancer 1991 ; 27:1629-33.
41. Wimalawansa SJ. Significance of plasma PTH-rP in patients with hypercalcemia of malignancy treated with bisphosphonates. Cancer 1994 ; 73:223-30.
42. Ralston SH, Thiébaud D, Hermann Z et al. Dose-reponse study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997 ; 75:295-300.
43. O'Rourke NP, McCloskey EV, Vasirakan S et al. Effective treatment of malignant hypercalcemia with a a single intravenous infusion of clodronate. Br J Cancer 1993 ; 67:560-3.
44. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcemia with the bisphosphonate pamidronate: dose-response relationship and influence of the tumor type. Ann Oncol 1994 ; 5:359-63.
45. Wall J, Ratcliffe WA, Howell A et al. Response to intravenous bisphosphonate therapy in hypercalcemic patients with and without bone metastases: the role of parathyroid hormone related protein. Br J Cancer 1994 ; 70:169-72.
46. Paterson AHE, Powles TJ E, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993 ; 11:59-65.
47. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993 ; 11:491-8.
48. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998 ; 16:1038-44.
49. Hultbom R, Ryden S, Gunderson S, Holmberg E, Wallgren UB. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomized prospective double blind placebo controlled trial. Eur J Cancer 1995 ; 31A (Suppl 5) S 376.
50. Theriault RL, Lipton A, Hortobagyi GN et al. For the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized , placebo-controlled trial. J Clin Oncol 1999 ; 17:846-54.
51. Lipton A. Aredia: the once-monthly infusion for the treatment of bone metastases. Curr Opin Oncol 1998 ; 10(Supl 1) S1-5.
52. Roberston AG, Reed NS, Ralston SH. Effects of oral clodronate on metastatic bone pain. A double-blind, placebo controlled study. J Clin Oncol 1995 ; 13:2427-30.
53. Coleman RE, Houston S, Puronit OP et al. A randomized phase II evaluation of oral pamidronate for advanced bone metastases from breast cancer. Eur J Cancer 1998 ; 84:820-4.
54. Coleman RE, Purohit OP, Black C et al. Double-blind , randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1998 ; 10:311-6.
55. Powles TJ, Paterson AHG, Nevantaus A et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 1997 ; 17:1998.
56. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 ; 339:357-63.
57. Saarto T, Blommquist C, Virkkunen P, Elomaa I. No reduction of bones metastases with adjuvant clodronate treatment in node positive breast cancer patients. Proc Am Soc Clin Oncol 1999 ; 18, 128a, Abst 489.
58. Conte PF, Latreille J, Maurik L et al. Delay in progresion of bone metastases in breast cancer patients treated with intravenous pamidronate results from a multi-national randomised controlled trial. J Clin Oncol 1996 ; 14:2552-9.
59. Powles TJ, McCloskey E, Paterson AH et al. Oral pamidronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998 ; 90:704-8.
60. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study. J Clin Oncol 1997 ; 15:955-62.
61. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997 ; 15:1341-7.
62. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post - menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997 ; 75:602-5.
63. Paule B, Clerc D. Cancer du rein : métastases osseuses , immunothérapie et interleukine 6. Ann Med Interne 1999 ; 150:4-9.
64. Miki S, Iwano M, Miki Y et al. IL-6 functions as an autocrine growth factor in renal carcinoma. FEBS Letter 1989 ; 250:607-10.
65. Weisglass M, Schamhart D, Lowick C, Papapoulos S, Vos P, Kurth KH. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone-related peptide by a human renal cell carcinoma implanted into nude mice . J Urol 1995 ; 153:854-7.
66. Weisglass M, Schamhart DHJ, Clemens WGM et al. The role of interleukin-6 in induction of hypercalcemia in renal cell carcinoma transplanted into nude mice. Endocrinology 1997 ; 138:1879-85.
67. Paule B, Clerc D, Rudant C et al. Enhanced expression of interleukin - 6 protein in bone and serum of metastatic renal cell carcinoma. Human Pathol 1998 ; 29:421-4.
68. Passen G, Girasole G, Uliette V et al. Bisphosphonates inhibit IL-6 production by human osteoblastic cells MGC3. J Bone Miner Res 1994 ; 9:suppl 1, S230.
69. Lissoni P, Cazzanga M, Barni S et al. Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumors patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1997 ; 33:304-06.
70. Percival RC, Urwin GH, Harris S et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987 ; 13:41-4.
71. Kylmala T, Taube T, Tammela TL et al. Concommitant iv and oral clodronate in the relief of bone pain ; a double blind placebo controlled study in patients with prostate cancer. Br J Cancer 1997 ; 76:939-42.
72. Lahtinen R, Laasko M, Palva I et al. Randomized placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1994 ; 340:1049-52.
73. Heim ME, Clemens MR, Queisser W et al. Prospective réandomized trial of dichloroethylene bisphosphonate (clodroante) in patients with multiple myeloma requiring treatment. A multicenter study. Onkology 1995 ; 18:439-48.
74. McCloskey EV, Maclennan CM, Drayson MT et al. A randomized trial of clodronate in multiple myeloma Br J Haematol 1998 ; 100:817-23.
75. Berenson JR, Lichtenstein A, Poreter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1998 ; 334:448-93.
76. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998 ; 16:593-8.
77. Savage AD, Belson DJ, Vescio RA et al. Pamidronate reduce IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996 ; 80, Abst 409.
78. Brincker H, Westin J, Abildgaert N et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind-placebo-controlled trial. Br J Haematol 1998 ; 101:280-6.
79. Berenson J, Webb I, Henick K et al. A phase II dose ranging trial of single agent pamidronate for relapsed/ refractory multiple myeloma. Am Soc Hematol 1998 ; Abst 436.
80. Fontana A, Hermann Z, Menssen HD et al. Effects of intravenous ibandronate on skeletal related events (SRE) and survival in patients with advanced multiple myeloma. Am Soc Hematol Abst 1998 ; 434.
81. Body JJ. Clinical research update: Zoledronate; Cancer 1997 ; 80 (Suppl) 1699-701.
82. Burckard, Ibandronate in oncology. Cancer 1997 ; 80(Suppl): 1696-8.